Published Studies Related to Novolin (Insulin Human)
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose
cotransporter 2, when used in conjunction with insulin therapy in patients with
type 2 diabetes. 
CONCLUSIONS: Canagliflozin added to insulin therapy improved glycemic control and
Intranasal insulin enhanced resting-state functional connectivity of hippocampal
regions in type 2 diabetes. 
Type 2 diabetes mellitus (T2DM) alters brain function and manifests as brain
Efficacy and safety of alogliptin added to insulin in Japanese patients with type
2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial
followed by an open-label, long-term extension phase. 
with insulin and diet or exercise... CONCLUSIONS: Alogliptin 25 mg/day was effective and well tolerated when added to
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin
resistance in type 2 diabetic patients. 
CONCLUSION: Vildagliptin, in addition to metformin, was more effective than
Effects of synbiotic supplementation on insulin resistance in subjects with the
metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. 
To evaluate the effects of synbiotic supplementation on insulin resistance and
lipid profile in individuals with the metabolic syndrome, we conducted a
randomised, double-blind, placebo-controlled pilot study on thirty-eight subjects
with the metabolic syndrome; they were supplemented with either synbiotic
capsules containing 200 million of seven strains of friendly bacteria plus
fructo-oligosaccharide or placebo capsules twice a day for 28 weeks...
Clinical Trials Related to Novolin (Insulin Human)
Comparison Study of Insulin Glargine and NPH Insulin [Enrolling by invitation]
This study will compare the safety, effectiveness, and cost of two different types of
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics [Terminated]
This is an open label, randomized, parallel group comparison of the immunogenicity safety of
Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based
human insulin products (marketed in USA) in type 1 diabetics.
There are two phases of the study, which are as follows:
1. Phase 1 is a comparative phase in which there will be 2 arms (which are described in
the section below).
2. Phase 2 is a follow up phase only applicable to Wosulin Arm.
The study will last for 54 weeks for the patients enrolled in Wosulin arm and approximately
28 weeks for the patients enrolled in the comparator arm.
Two hundred and forty two patients will be enrolled considering an estimated dropout rate of
15% for a sample size of approximately 105 evaluable patients per arm. The total planned
enrollment period for this study is approximately 3 months (90 days).
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes [Completed]
The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty
liver disease (or NAFLD, a common condition in T2DM; Cusi K, Current Diabetes Reports 2009)
has not been systematically studied before, and in particular, never when using the new
insulin formulations detemir (Levemir®) or aspart (Novolog®). This study was to determine
the effect on hepatic steatosis and insulin secretion/action of lowering the fasting plasma
glucose (FPG) to target with once daily basal insulin detemir alone or combining insulin
detemir with premeal insulin aspart in patients with uncontrolled type 2 diabetes mellitus
In the first 3 months the investigators will optimize metabolic control in all patients with
intensive basal (bedtime) detemir insulin aiming at a normal fasting plasma glucose. After
this treatment period, patients will be randomized in the second 3 months in a 2: 1 ratio to
insulin detemir or detemir plus aspart. The investigators propose that insulin will improve
day-long glycemic control and A1c, reduce hepatic steatosis (NAFLD) (primary endpoint) and
insulin secretion/sensitivity being well tolerated while causing minimal weight gain and
hypoglycemia (secondary endpoints). The study will allow to assess if there is an additional
benefit of adding pre-meal rapid-acting insulin aspart to basal insulin to these endpoints.
Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia [Recruiting]
No consensus guidelines exist for management of post-transplant glucocorticoid induced
hyperglycemia, but most published reviews recommend insulin as first line therapy. A
variety of insulin regimens have been proposed, including mealtime short-acting regular or
analog insulin, once daily neutral protamine hagedorn (NPH) insulin, pre-mixed insulin, or
basal insulin alone such as glargine or detemir. However, no randomized trial has ever
examined different insulin regimens to determine which most effectively controls
post-transplant steroid-induced hyperglycemia. Consequently, the proposed study intends to
examine three commonly used insulin regimens used for managing post-transplant once-daily
glucocorticoid-induced hyperglycemia to determine which is most effective:
- Group 1: Intermediate-acting (NPH) insulin at breakfast
- Group 2: Short-acting insulin (regular or aspart) before meals
- Group 3: Insulin glargine at breakfast
Among three commonly used insulin regimens, which is most effective for managing
post-transplant once-daily glucocorticoid-induced hyperglycemia?
Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome [Suspended]
The study aims to demonstrate that a simple intravenous insulin algorithm can be implemented
in Latin America and will result in safe and better glucose control in patients with Acute
Coronary Syndrome (ACS) compared with SC insulin.